Hormone Insight Editorial Team

SURPASS Post Hoc Analysis

Semaglutide + Empagliflozin for NAFLD in T2D

STEP-HFpEF Pooled Analysis: Semaglutide Improves Symptoms, Function, and Inflammation in Obesity-HFpEF

Semaglutide and Obesity-Related Heart Failure

Tirzepatide Phase 1 Trial

A phase 1 clamp trial shows tirzepatide improves beta-cell function and insulin sensitivity more than semaglutide, explaining its glucose-lowering. PICO summary and commentary.

ADA Releases 2025 Guidelines to Prevent or Delay Diabetes and Comorbidities

A clinical guideline update on the prevention or delay of diabetes and associated comorbidities was published in January 2025 by the American Diabetes Association (ADA) Professional Practice Committee. These guidelines, published in Diabetes Care (2025;48(Suppl. 1):S50–S58).

Semaglutide vs Canagliflozin for Body Composition in T2D: Fat Loss Similar Despite Greater Weight Loss with GLP-1 RA

Semaglutide vs Mealtime Insulin Aspart for Basal Insulin Intensification: SUSTAIN 11 Trial

SUSTAIN 8: Semaglutide vs Canagliflozin Head-to-Head for Glycemic Control and Weight Loss

Study Shows Tirzepatide Improves Heart Failure Outcomes and Quality of Life in Obese Patients

In patients with heart failure with preserved ejection fraction (HFpEF) and obesity, tirzepatide significantly reduced the composite risk of cardiovascular death or worsening heart failure and improved health status compared to placebo, though it was associated with higher gastrointestinal side effects.